# Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/maximum-tolerated-dose-of-a-humanized-anti-vascular-endothelial-growth-factor/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Philip J. Rosenfeld,Steven D. Schwartz,Mark S. Blumenkranz,Joan W. Miller,Julia A. Haller,James D. Reimann,William H. Greene,N. Shams |
| Citations | 223 |
| DOI | 10.1016/j.ophtha.2005.01.043 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2015655380 |
| PMID | 15885778 |
| Type | article |
| Year | 2005 |

## Paper authors

- [Steven D. Schwartz](https://scholariq.org/researchers/steven-d-schwartz/)

## Paper journal

- [Ophthalmology](https://scholariq.org/journals/ophthalmology/)

## Paper primary topic

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)

## Paper topics

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Ophthalmology and Visual Impairment Studies](https://scholariq.org/topics/ophthalmology-and-visual-impairment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.